A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome
- 847 Downloads
Mucopolysaccharidosis II (MPS II, Hunter syndrome; OMIM 309900) is an X-linked lysosomal storage disease caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), leading to accumulation of glycosaminoglycans (GAGs). For enzyme replacement therapy (ERT) of Hunter syndrome, two recombinant enzymes, idursulfase (Elaprase®, Shire Human Genetic Therapies, Lexington, MA) and idursulfase beta (Hunterase®, Green Cross Corporation, Yongin, Korea), are currently available in Korea. To compare the biochemical and physicochemical differences between idursulfase and idursulfase beta, we examined the formylglycine (FGly) content, specific enzyme activity, mannose-6-phosphate (M6P) content, sialic acid content, and in vitro cell uptake activity of normal human fibroblasts of these two enzymes.
The FGly content, which determines the enzyme activity, of idursulfase beta was significantly higher than that of idursulfase (79.4 ± 0.9 vs. 68.1 ± 2.2 %, P < 0.001). In accordance with the FGly content, the specific enzyme activity of idursulfase beta was significantly higher than that of idursulfase (42.6 ± 1.1 vs. 27.8 ± 0.9 nmol/min/μg protein, P < 0.001). The levels of M6P and sialic acid were not significantly different (2.4 ± 0.1 vs 2.4 ± 0.3 mol/mol protein for M6P and 12.3 ± 0.7 vs. 12.4 ± 0.4 mol/mol protein for sialic acid). However, the cellular uptake activity of the normal human fibroblasts in vitro showed a significant difference (Kuptake, 5.09 ± 0.96 vs. 6.50 ± 1.28 nM protein, P = 0.017).
In conclusion, idursulfase beta exhibited significantly higher specific enzyme activity than idursulfase, resulting from higher FGly content. These biochemical differences may be partly attributed to clinical efficacy. However, long-term clinical evaluations of Hunter syndrome patients treated with these two enzymes will be needed to demonstrate the clinical implications of significant difference of the enzyme activity and the FGly content.
KeywordsHunter syndrome MPS II Iduronate-2-sulfatase Formylglycine Mannose-6-phosphate Enzyme replacement therapy
This study was sponsored by Green Cross Corp. (Yongin, Korea). This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A101779). We thank Myeong-suk Moon and Jun-mo Bae for helpful supporting on specific enzyme activity assay and in vitro cell uptake assay.
All of the authors have nothing to disclose.
- 2.Neufeld, E.F., Muenzer, J.: The mucopolysaccharidoses. In: Scriver, C.R. (ed.) The metabolic and molecular bases of inherited disease, pp. 3421–52. McGraw-Hill, New York (2001)Google Scholar
- 4.Jones, S.A., Almassy, Z., Beck, M., Burt, K., Clarke, J.T., Giugliani, R., Hendriksz, C., Kroepfl, T., Lavery, L., Lin, S.P., Malm, G., Ramaswami, U., Tincheva, R., Wraith, J.E.: Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the hunter outcome survey (HOS). J Inherit Metab Dis 32(4), 534–543 (2009). doi: 10.1007/s10545-009-1119-7 PubMedCrossRefGoogle Scholar
- 7.Sohn, Y.B., Cho, S.Y., Park, S.W., Kim, S.J., Ko, A.R., Kwon, E.K., Han, S.J., Jin, D.K.: Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis 8, 42 (2013). doi: 10.1186/1750-1172-8-42 PubMedCentralPubMedCrossRefGoogle Scholar
- 9.Muenzer, J., Wraith, J.E., Beck, M., Giugliani, R., Harmatz, P., Eng, C.M., Vellodi, A., Martin, R., Ramaswami, U., Gucsavas-Calikoglu, M., Vijayaraghavan, S., Wendt, S., Puga, A.C., Ulbrich, B., Shinawi, M., Cleary, M., Piper, D., Conway, A.M., Kimura, A.: A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med Off J Am Coll Med Genet 8(8), 465–473 (2006). doi: 10.1097/01.gim.0000232477.37660.fb Google Scholar
- 22.Schlotawa, L., Ennemann, E.C., Radhakrishnan, K., Schmidt, B., Chakrapani, A., Christen, H.J., Moser, H., Steinmann, B., Dierks, T., Gartner, J.: SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency. Eur J Hum Genet: EJHG 19(3), 253–261 (2011). doi: 10.1038/ejhg.2010.219 PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Roeser, D., Preusser-Kunze, A., Schmidt, B., Gasow, K., Wittmann, J.G., Dierks, T., von Figura, K., Rudolph, M.G.: A general binding mechanism for all human sulfatases by the formylglycine-generating enzyme. Proc Natl Acad Sci U S A 103(1), 81–86 (2006). doi: 10.1073/pnas.0507592102 PubMedCentralPubMedCrossRefGoogle Scholar
- 25.Jones, A.J., Papac, D.I., Chin, E.H., Keck, R., Baughman, S.A., Lin, Y.S., Kneer, J., Battersby, J.E.: Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17(5), 529–540 (2007). doi: 10.1093/glycob/cwm017 PubMedCrossRefGoogle Scholar